Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems).

Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems).

Clear Cell Carcinoma of the Female Genital Tract (Not Everything Is as Clear as it Seems).

Adv Anat Pathol. 2012 Sep;19(5):296-312

Abstract

Clear cell carcinoma has a storied history in the female genital tract. From the initial designation of ovarian clear cell adenocarcinoma as "mesonephroma" to the linkage between vaginal clear cell carcinoma and diethylstilbestrol exposure in utero, gynecologic tract clear cell tumors have puzzled investigators, posed therapeutic dilemmas for oncologists, and otherwise presented major differential diagnostic challenges for pathologists. One of the most common errors in gynecologic pathology is misdiagnosis of clear cell carcinoma, on both frozen section and permanent section. Given the poor response to platinum-based chemotherapy for advanced-stage disease and increased risk of thromboembolism, accurate diagnosis of clear cell carcinoma is important in the female genital tract. This review (1) presents the clinical and pathologic features of female genital tract clear cell carcinomas; (2) highlights recent molecular developments; (3) identifies areas of potential diagnostic confusion; and (4) presents solutions for these diagnostic problems where they exist.

PMID: 22885379 [PubMed 

Beyond Office Hours: New App, Patient Portal, to Allow U-M Patients Mobile Access to Health Records

http://www.newswise.com/articles/view/592545/?sc=rsla&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+NewswiseLatestNews+%28Newswise%3A+Latest+News%29&utm_content=Google+Reader

Empathy in Healthcare's a Waste, Unless It's a Strategic Focus - Forbes

nless-its-a-strategic-focus/

Quality of Life in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is It Worth the Risk?

Quality of Life in Patients after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is It Worth the Risk?

Abstract

Objective  

To investigate the course of health-related quality of life (HQL) over time in patients with peritoneal carcinomatosis (PC)
after complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods  

Prospective, single-center, nonrandomized cohort study using the European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire.

Results  

Ninety patients who underwent CRS and HIPEC for PC in our institution were enrolled in the study. Mean age was 56 years (range
27–77 years) (61 % female). Primary tumor was colorectal in 21 %, ovarian in 19 %, pseudomyxoma peritonei in 16 %, an appendix
tumor in 16 %, gastric cancer in 10 %, and peritoneal mesothelioma in 13 % of cases. Mean peritoneal carcinomatosis index
was 22 (range 2–39). Mean global health status score was 69 ± 25 preoperatively and 55 ± 20, 66 ± 22, 66 ± 23, 71 ± 23, and
78 ± 21 at months 1, 6, 12, 24, and 36, respectively. Physical and role function recovered significantly at 6 months and were
close to baseline at the 24-month measurement. Emotional function starting from a low baseline recovered to baseline by month
12. Cognitive and social function had slow recovery on follow-up. Fatigue, diarrhea, dyspnea, and sleep disturbance were symptoms
persistent at 6-month follow-up, improving later on in survivors.

Conclusions  

Survivors after CRS and HIPEC have postoperative quality of life similar to preoperatively, with most of the reduced elements
recovering after 6–12 months. We conclude that reduced quality of life of patients after CRS and HIPEC should not be used
as an argument to deny surgical therapy to these patients.

Ovarian cancer: emerging molecular-targeted therapies June 2012

‘Real inequalities’ a threat to medicare’s mission, incoming CMA chief says - The Globe and Mail

From The Globe and Mail:
'Real inequalities' a threat to medicare's mission, incoming CMA chief 

National Guideline Clearinghouse | Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Electronic health records: what does your signature signify?

Ovarian Cancer Clinical Trial: Patient Reported Symptoms in Ovarian Cancer (PRECISION) - ongoing

http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01422265

Public funding for genomics: where does Canada stand?

Public funding for genomics: where does Canada stand?

After more than six years of funding exclusive projects in forestry and agriculture, Genome Canada has now announced a $67.5 million funding competition for large-scale genomics projects in human health, with focus on personalised medicine.ⁱ The human genomics community of this country understandably rejoiced at this long overdue announcement that gives them, for the first time in years, the means to compete internationally (http://www.genomecanada.ca/en/portfolio/research/2012-competition.aspx). Canada has been fairly generous in funding human-health related research but mostly through the Canadian Institutes of Health Research (CIHR) or the Canada Foundation for Innovation, neither of which has within its mandate to fund the type of specific multimillion-dollar project that is usually thought of as genomics. The typical CIHR grant, for example, rarely exceeds $1 million (200 000 over 5 years) in direct costs.

The elation over the announcement of this funding opportunity in late 2011 soon gave way to sober...

Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women

Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women

Background

Postmenopausal hormone (PMH) therapy may reduce colorectal cancer (CRC) risk, but existing data are inconclusive.

Objectives

To evaluate associations between PMH therapy and incident CRC, overall and by molecularly defined subtypes, in the population-based Iowa Women's Health Study of older women.

Methods

Exposure data were collected from Iowa Women's Health Study participants (55–69 years) at baseline (1986). Archived, paraffin-embedded tissue specimens for 553 CRC cases were collected and analysed to determine microsatellite instability (MSI-L/MSS or MSI-H), CpG island methylator phenotype (CIMP-negative or CIMP-positive) and BRAF mutation (BRAF-wildtype or BRAF-mutated) status. Multivariable Cox regression models were fit to estimate RRs and 95% CIs.

Results

PMH therapy (ever vs never use) was inversely associated with incident CRC overall (RR=0.82; 95% CI 0.72 to 0.93), with a significantly lower risk for MSI-L/MSS tumours (RR=0.75; 95% CI 0.60 to 0.94), and borderline significantly lower risks for CIMP-negative (RR=0.79; 95% CI 0.63 to 1.01) and BRAF-wildtype (RR=0.83; 95% CI 0.66 to 1.04) tumours. For PMH therapy >5 years, the subtype-specific risk estimates for MSI-L/MSS, CIMP-negative and BRAF-wildtype tumours were: RR=0.60, 95% CI 0.40 to 0.91; RR=0.68, 95% CI 0.45 to 1.03; and RR=0.70, 95% CI 0.47 to 1.05, respectively. PMH therapy was not significantly associated with the MSI-H, CIMP-positive or BRAF-mutated CRC subtypes.

Conclusions

In this prospective cohort study, PMH therapy was inversely associated with distinct molecularly defined CRC subtypes, which may be related to differential effects from oestrogen and/or progestin on heterogeneous pathways of colorectal carcinogenesis.

Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer’s perspective

Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective

Abstract  

PET and MRI are established clinical tools which provide complementary information, but clinical workflow limits widespread
clinical application of both modalities in combination. The two modalities are usually situated in different hospital departments
and operated and reported independently, and patients are referred for both scans, often consecutively. With the advent of
PET/MR as a new hybrid imaging modality there is now a possibility of addressing these concerns. There are two different design
philosophies for integrated PET/MR imaging—positioning PET inside the MRI magnet or in tandem, similar to PET/CT. The Ingenuity
TF PET/MR by Philips Healthcare is a sequential PET/MR tomograph combining state-of-the-art time-of-flight PET and high-field
MRI with parallel transmission capabilities. In this review article we describe the technology implemented in the system,
for example RF and magnetic shielding, MR-based attenuation correction, peculiarities in scatter correction, MR system optimisation,
and the philosophy behind its design. Furthermore, we provide an overview of how the system has been used during the last
two years, and expectations of how the use of PET/MR may continue in the years to come. On the basis of these observations
and experiences we discuss the utility of the system, clinical workflow and acquisition times, and possible ways of optimization.

• Content Type Journal Article
• Category Review Article
• Pages 1-19
• DOI 10.1007/s10334-012-0330-y

• Journal Magnetic Resonance Materials in Physics, Biology and Medicine

Oncology imaging in the abdomen and pelvis: where cancer hides

Oncology imaging in the abdomen and pelvis: where cancer hides

Abstract  

As the incidence of cancer continues to increase, imaging will play an ever more important role in the detection, diagnosis,
staging, surveillance, and therapeutic monitoring of cancer. Diagnostic errors in the initial discovery of cancer or at follow-up
assessments can lead to missed opportunities for curative treatments or altering or reinitiating therapies, as well as adversely
impact clinical trials. Radiologists must have an understanding of cancer biology, treatments, and imaging appearance of therapeutic
effects and be mindful that metastatic disease can involve virtually any organ system. Knowledge of patient history and tumor
biology allows for optimizing imaging protocols. The majority of cancer imaging utilizes computed tomography, where contrast
enhancement characteristics of lesions can be exploited and detection of subtle lesions can involve manipulation of window
width and level settings, multiplanar reconstruction, and maximum intensity projections. For magnetic resonance imaging, diffusion-weighted
imaging can render lesions more conspicuous, improve characterization, and help assess therapeutic response. Positron emission
tomography with ¹⁸F-labeled fluorodeoxyglucose and sodium fluoride are invaluable in detecting occult existing and new cancerous lesions, characterizing
indeterminate lesions, and assessing treatment effects. The most common anatomic "hiding places" for cancer include metastases
to solid organs, such as the kidneys and pancreas, gastrointestinal tract, peritoneum and retroperitoneum, neural axis, muscular
body wall, and bones. Consistent work habits, employment of appropriate technologies, and particular attention to the above
anatomic areas can enhance detection, staging, and reassessments of these complex and often stealthy diseases, ensuring the
radiologists' integral role in the cancer care team.

• Journal Abdominal Imaging
• Online ISSN 1432-0509

Journal of Cancer Education - SpringerLink

http://www.springerlink.com/content/121578/


Sent from my iPhone

Dietary Lifestyle and Colorectal Cancer Onset, Recurrence, and Survival: Myth or Reality?

Dietary Lifestyle and Colorectal Cancer Onset, Recurrence, and Survival: Myth or Reality?

Abstract

Background and Purpose  

Interest in the possibility that diet might help to reduce the risk of colorectal cancer dates back to 1970 based on both
the large variation in rates of specific cancers in different countries and the impressive changes observed in the incidence
of cancer in migrants from low- to high-risk areas. Here, we report the state of art of literature data about this topic.

Methods  

Three sections have been separately considered: chemoprevention of first tumor onset, chemoprevention of recurrence after
surgery, and chemoprevention of polyp recurrence in the course of the follow-up of subjects with elevated risk. A particular
attention has been pointed to dietary factors and survival, whose relevance is showing a growing interest.

Results  

The relationship between diet and colorectal cancer has been extensively studied about the onset, sometimes with controversial
results. Its influence on recurrence and survival has been examined in only few studies.

Conclusions  

Literature data are convincing for a protective role on the onset of preneoplastic and neoplastic lesions for some foods such
as fibers, vitamin A and D, folic acid, calcium, antioxidants, and promising perspectives for some substances such as phyto-estrogens.
Less evidence-based data are available on the possibility to avoid the recurrence of the disease or to affect its mortality
with dietary habits. Future perspectives will be directed be not only to identify new dietary style able to prevent the onset
of neoplastic lesion of the colon but also to realize an effective chemoprevention.

• Content Type Journal Article
• Category Review Article
• Pages 1-11
• DOI 10.1007/s12029-012-9425-y

A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcomes system in assessing patient recovery after major gynecologic cancer surgery.

http://www.ncbi.nlm.nih.gov/m/pubmed/22871467/

Ovarian Cancer Biotargets of Cancer in Current Clinical Practice

Ovarian Cancer Biotargets of Cancer in Current Clinical Practice

In Biotargets of Cancer in Current Clinical Practice (2012), pp. 381-401, doi:10.1007/978-1-61779-615-9_14

Ovarian cancer is the fifth most common cancer in women and is the most lethal of all gynecologic cancers. Early-stage ovarian cancer is curable while women who are diagnosed with advanced ovarian cancer continue to have poor long-term survival due to recurrence of disease. Unfortunately, most women are diagnosed with advanced-stage disease. Early detection is a primary objective for clinicians and scientists, yet single modality (CA-125, transvaginal ultrasound) screening tests have been ineffective. More recent novel approaches combining modalities and utilizing serial serum sampling are being tested and hold great promise. In addition, the recent application of proteomics to this clinical question has the potential to identify new and important biotargets. Unfortunately, the majority of ovarian cancer patients have advanced-stage disease, and although most will die of their disease, their survival is quite heterogenous. The ability to stratify patients according to prognosis could help guide therapy. The current "gold standard" for prognosis uses patient, surgical, and tumor characteristics, yet these have the tendency to be notoriously inaccurate. This prognostic uncertainty and the drive to identify predictive factors by which we can select novel and targeted therapy have stimulated researchers to look beyond traditional markers and test and validate molecular and genomic biomarkers, which are anticipated to soon complement or even eclipse traditional factors clarifying prognosis and select treatments. For patients with advanced-stage disease, a multitude of prognostic factors have been characterized. While promising, none of these biotargets have been validated at present to be clinically useful. More recent application of genomic technologies is likely to yield clinically relevant signatures and/or biotargets which will provide the basis for personalization of care for these patients.
Jessica Oribabor, Allison Ambrosio, Cesar Castro, Michael Birrer

Environmentally Induced Epigenetic Transgenerational Inheritance of Ovarian Disease

"Environmentally Induced Epigenetic Transgenerational Inheritance of Ovarian Disease"

Incidence, appropriateness, and consequences of recommendations for additional imaging tests in oncological PET/CT reports

Incidence, appropriateness, and consequences of recommendations for additional imaging tests in oncological PET/CT reports

Publication year: 2012
Source:Clinical Radiology
A.B. Shinagare, P.B. Shyn, C.A. Sadow, E.J. Wasser, P. Catalano
Aim To assess the incidence, appropriateness, and outcomes of recommendations for additional imaging tests (RAI) in oncological combined 2-[¹⁸F]-fluoro-2-deoxy-d-glucose positron-emission tomography and computed tomography (FDG-PET/CT) reports. Material and methods In this retrospective study, conducted with institutional review board approval, the first oncological FDG-PET/CT reports in 2008 for 250 consecutive patients were reviewed to identify RAI. PET/CT reports containing RAI were retrospectively reviewed by two blinded readers. PET/CT findings prompting RAI, appropriateness of RAI, results of additional imaging tests actually performed, and the ultimate clinical significance of findings prompting RAI were recorded. Confirmation of clinical significance required pathology confirmation, unequivocal imaging progression, imaging stability for 12 months, or clinical follow-up for 24 months or end of life. Results Eighty-four RAI were identified for 88 PET/CT findings in 29.6% (74/250) of PET/CT reports, of which 51.2% (43/84) were deemed unnecessary by reviewers. Referring clinicians only followed 31% (26/84) of RAI by requesting additional imaging tests, and these tests resolved the PET/CT question in 76.9% (20/26) of those cases. Only 11.4% (10/88) of all findings prompting RAI proved to be clinically significant. Only 4.7% (2/43) of RAI deemed unnecessary by reviewers and 5.2% (3/58) of RAI not pursued by clinicians were found to be clinically significant; however, PET/CT alone was sufficient for diagnosis or guiding appropriate clinical management in each of these cases. Conclusion RAI were found in 29.6% of oncological PET/CT reports. No potential adverse impact on patient management or outcome, by not issuing or following RAI, was identified in the 51.2% of RAI deemed unnecessary by study readers or in the 69% of RAI not pursued by referring clinicians.

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised triall

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

Publication year: 2012
Source:European Journal of Cancer
Mia Fahlén, Tommy Fornander, Hemming Johansson, Ulla Johansson, Lars-Erik Rutqvist, Nils Wilking, Eva von Schoultz
Background The management of hormonal deficiency symptoms in breast cancer survivors is an unsolved problem. While hormone replacement therapy (HRT) may increase the risk of breast cancer in healthy women, its effects on recurrence is unclear. Observational studies have suggested decreased recurrence rates from HRT. The few clinical trials in this field have all been closed preterm. Methods The Stockholm trial was started in 1997 and designed to minimise the dose of progestogen in the HRT arm. Disease-free women with a history of breast cancer were randomised to HRT (n =188) or no HRT (n =190). The trial was stopped in 2003 when another Swedish study (HABITS, the Hormonal Replacement After Breast Cancer – Is it Safe?) reported increased recurrence. However the Stockholm material showed no excess risk after 4years of follow-up. A long term follow-up has now been performed. Findings After 10.8years of follow-up, there was no difference in new breast cancer events: 60 in the HRT group versus 48 among controls (hazard ratio (HR)=1.3; 95% confidence interval (CI)=0.9–1.9). Among women on HRT, 11 had local recurrence and 12 distant metastases versus 15 and 12 for the controls. There were 14 contra-lateral breast cancers in the HRT group and four in the control group (HR=3.6; 95% CI=1.2–10.9; p =0.013). No differences in mortality or new primary malignancies were found. Interpretation The number of new events did not differ significantly between groups, in contrast to previous reports. The increased recurrence in HABITS has been attributed to higher progestogen exposure. As both trials were prematurely closed, data do not allow firm conclusions. Both studies found no increased mortality from breast cancer or other causes from HRT. Current guidelines typically consider HRT contraindicated in breast cancer survivors. Findings suggest that, in some women symptom relief may outweigh the potential risks of HRT.

Whole mind and shared mind in clinical decision-making

Whole mind and shared mind in clinical decision-making

Publication year: 2012
Source:Patient Education and Counseling
Ronald Mark Epstein
Objective To review the theory, research evidence and ethical implications regarding "whole mind" and "shared mind" in clinical practice in the context of chronic and serious illnesses. Methods Selective critical review of the intersection of classical and naturalistic decision-making theories, cognitive neuroscience, communication research and ethics as they apply to decision-making and autonomy. Results Decision-making involves analytic thinking as well as affect and intuition ("whole mind") and sharing cognitive and affective schemas of two or more individuals ("shared mind"). Social relationships can help processing of complex information that otherwise would overwhelm individuals' cognitive capacities. Conclusions Medical decision-making research, teaching and practice should consider both analytic and non-analytic cognitive processes. Further, research should consider that decisions emerge not only from the individual perspectives of patients, their families and clinicians, but also the perspectives that emerge from the interactions among them. Social interactions have the potential to enhance individual autonomy, as well as to promote relational autonomy based on shared frames of reference. Practice implications Shared mind has the potential to result in wiser decisions, greater autonomy and self-determination; yet, clinicians and patients should be vigilant for the potential of hierarchical relationships to foster coercion or silencing of the patient's voice.

Addressing the Financial Consequences of Cancer: Qualitative Evaluation of a Welfare Rights Advice Service

Addressing the Financial Consequences of Cancer: Qualitative Evaluation of a Welfare Rights Advice Service

by Suzanne Moffatt, Emma Noble, Martin White

Background

The onset, treatment and trajectory of cancer is associated with financial stress among patients across a range of health and welfare systems and has been identified as a significant unmet need. Welfare rights advice can be delivered effectively in healthcare settings, has the potential to alleviate financial stress, but has not yet been evaluated. We present an evaluation of a welfare rights advice intervention designed to address the financial consequences of cancer.

Methods

Descriptive study of welfare outcomes among 533 male and 641 female cancer patients and carers aged 4–95 (mean 62) years, who accessed the welfare rights advice service in North East England between April 2009 and March 2010; and qualitative interview study of a maximum variation sample of 35 patients and 9 carers.

Results

Over two thirds of cancer patients and carers came from areas of high socio-economic deprivation. Welfare benefit claims were successful for 96% of claims made and resulted in a median increase in weekly income of £70.30 ($109.74, €84.44). Thirty-four different types of benefits or grants were awarded. Additional resources were perceived to lessen the impact of lost earnings, help offset costs associated with cancer, reduce stress and anxiety and increase ability to maintain independence and capacity to engage in daily activities, all of which were perceived to impact positively on well-being and quality of life. Key barriers to accessing benefit entitlements were knowledge, system complexity, eligibility concerns and assumptions that health professionals would alert patients to entitlements.

Conclusions

The intervention proved feasible, effectively increased income for cancer patients and was highly valued. Addressing the financial sequelae of cancer can have positive social and psychological consequences that could significantly enhance effective clinical management and suitable services should be routinely available. Further research is needed to evaluate health outcomes definitely and assess cost-effectiveness.

"The Coach And The Critic" Blog Comes To Life Online: A Discussion About Caregivers That I Will Never Forget

http://m.cancer.org/AboutUs/DrLensBlog/post/2011/04/26/The-Coach-And-The-Critic-Blog-Comes-To-Life-Online-A-Discussion-About-Caregivers-That-I-Will-Never-Forget.aspx

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer.

Br J Cancer. 2012 Aug 9;

Authors: Harding V, Fenu E, Medani H, Shaboodien R, Ngan S, Li HK, Burt R, Diamantis N, Tuthill M, Blagden S, Gabra H, Urch CE, Moser S, Agarwal R

Abstract

Background:Paracentesis for malignant ascites is usually performed as an in-patient procedure, with a median length of stay (LoS) of 3-5 days, with intermittent clamping of the drain due to a perceived risk of hypotension. In this study, we assessed the safety of free drainage and the feasibility and cost-effectiveness of daycase paracentesis.Method:Ovarian cancer admissions at Hammersmith Hospital between July and October 2009 were audited (Stage 1). A total of 21 patients (Stage 2) subsequently underwent paracentesis with free drainage of ascites without intermittent clamping (October 2010-January 2011). Finally, 13 patients (19 paracenteses, Stage 3), were drained as a daycase (May-December 2011).Results:Of 67 patients (Stage 1), 22% of admissions and 18% of bed-days were for paracentesis, with a median LoS of 4 days. In all, 81% of patients (Stage 2) drained completely without hypotension. Of four patients with hypotension, none was tachycardic or symptomatic. Daycase paracentesis achieved complete ascites drainage without complications, or the need for in-patient admission in 94.7% of cases (Stage 3), and cost £954 compared with £1473 for in-patient drainage.Conclusions:Free drainage of malignant ascites is safe. Daycase paracentesis is feasible, cost-effective and reduces hospital admissions, and potentially represents the standard of care for patients with malignant ascites.British Journal of Cancer advance online publication, 9 August 2012; doi:10.1038/bjc.2012.343 www.bjcancer.com.

PMID: 22878372 [PubMed - as supplied by publisher]

Factors Associated with Publication of Plenary Presentations at the Society of Gynecologic Oncologists Annual Meeting

Sent to you via Google Reader

Factors Associated with Publication of Plenary Presentations at the Society of Gynecologic Oncologists Annual Meeting

Publication year: 2012

Objective To determine the rate and factors associated with publication of plenary abstract presentations from the Society of Gynecologic Oncologists annual meeting. Methods Plenary presentations were reviewed from 2000 to 2005. A Pubmed search was performed to identify subsequent peer-reviewed publication of these presentations. Chi-squared test and logistic regression were used for statistical analyses. Results Of 378 main, focused or express plenary presentations, 173 (45.8%) involved multiple and 205 (54.2%) single institutions. The types of study include: chart review (29.4%), cohort study (28.0%), translational (23.5%), and randomized clinical trial (6.9%). 309 (81.7%) of presentations were subsequently published. The median time from presentation to publication was 14months (range: 1–85). Studies from multiple vs. single institutions were more likely to be published (87.9% vs. 76.6%; p=0.005). In addition, randomized controlled trials were more likely to be published compared to chart review, cohort, and translation research (92.3% vs. 83.8%, 77.4%, and 74.2%; p<0.01). On multivariate analysis, multi-institutional studies (OR=2.28, 95% CI=1.28-4.04; p=0.005) and type of study (OR=1.64, 95% CI=1.19-2.26; p=0.002) were independent factors associated with publication. In addition, multi-institutional studies had longer times from presentation to publication compared to their counterparts. Conclusions A high percentage of plenary presentations at the Society of Gynecologic Oncologists annual meeting resulted in subsequent publication. Multi-institutional studies and randomized clinical trials were more likely to be published.

Highlights

► Over 80% of presentations at the annual Society of Gynecologic Oncologists meeting were published in peer-reviewed journals ► Single-institution studies were associated with a lower likelihood of publication ► Multi-institutional studies had a higher publication rate compared to other studies